IBL-302

• Target :

  PI3K|||Akt|||mTOR|||Pim

• Related Pathways :

  Cytoskeletal Signaling|||Chromatin/Epigenetic|||PI3K/Akt/mTOR signaling|||JAK/STAT signaling

• Bioactivity :

  IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].

• Smiles :

  CC=1C2=C3C(C=4SC(=CC4)CNC(=O)C=5C=C(S(=O)(=O)NC6=CC(C1S3)=CN=C6OC)C=CC5F)=NC=N2

• Molecular Formula :

  C25H18FN5O4S3

• Molecular Weight :

  567.64

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  1414455-21-2